Reversal of cognitive decline: A novel therapeutic program

Aging

Volumn 6, Issue 9, 2014, Pages 707-717

  Bredesen, Dale E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

Alzheimer's; Dementia; Mild cognitive impairment; Neurobehavioral disorders; Neurodegeneration; Neuroinflammation; Systems biology

Indexed keywords

AGED; ALZHEIMER DISEASE; CASE REPORT; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT;

AGED; ALZHEIMER DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT;

EID: 84907810598     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100690     Document Type: Review

References (56)

1. Prince MA, Emiliano; Guerchet, Maëlenn; Prina, Matthew. 2014; World Alzheimer Report 2014 United Kingdom: Alzheimer's Disease International.
2. James BD, Leurgans SE, Hebert LE, Scherr PA, Yaffe K and Bennett DA. Contribution of Alzheimer disease to mortality in the United States. Neurology. 2014; 82:1045-1050.
3. Shriver M. A Woman's Nation Takes on Alzheimer's. 2010; New York, USA: Alzheimer's Association.
4. 2014 Alzheimer's Disease Facts and Figures. Special Report on Women and Alzheimer's Disease. USA: Alzheimer's Association, 2014; pp. 1-80.
5. Bredesen DE, John, V. Next generation therapeutics for Alzheimer's disease. EMBO Mol Med. 2013; 5:795-798.
6. Lu DC, Rabizadeh S, Chandra S, Shayya RF, Ellerby LM, Ye X, Salvesen GS, Koo EH and Bredesen DE. A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. Nat Med. 2000; 6:397-404.
7. Galvan V, Gorostiza OF, Banwait S, Ataie M, Logvinova AV, Sitaraman S, Carlson E, Sagi SA, Chevallier N, Jin K, Greenberg DA and Bredesen DE. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci U S A. 2006; 103:7130-7135.
8. Bredesen DE. Neurodegeneration in Alzheimer's disease: caspases and synaptic element interdependence. Mol Neurodegener. 2009; 4:27.
9. Bredesen DE. Prionic Loops, Anti-Prions, and Dependence Receptors in Neurodegeneration. In: Legname GR, Detlev, ed. Prion Research of Stan Prusiner and his Colleagues. 2013; (Gernamy: Dusseldorf University Press), pp. 1-24.
10. Lu DC, Shaked GM, Masliah E, Bredesen DE and Koo EH. Amyloid beta protein toxicity mediated by the formation of amyloid-beta protein precursor complexes. Ann Neurol. 2003;54:781-789.
11. Bertrand E, Brouillet E, Caille I, Bouillot C, Cole GM, Prochiantz A and Allinquant B. A short cytoplasmic domain of the amyloid precursor protein induces apoptosis in vitro and in vivo. Mol Cell Neurosci. 2001; 18:503-511.
12. Nikolaev A, McLaughlin T, O'Leary DD and Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009; 457:981-989.
13. Guo H, Tittle TV, Allen H and Maziarz RT. Brefeldin Amediated apoptosis requires the activation of caspases and is inhibited by Bcl-2. Exp Cell Res. 1998; 245:57-68.
14. Tian Y, Crump CJ and Li YM. Dual role of alpha-secretase cleavage in the regulation of gamma-secretase activity for amyloid production. J Biol Chem. 2010; 285:32549-32556.
15. Deyts C, Vetrivel KS, Das S, Shepherd YM, Dupre DJ, Thinakaran G and Parent AT. Novel GalphaS-Protein Signaling Associated with Membrane-Tethered Amyloid Precursor Protein Intracellular Domain. J Neurosci. 2012; 32:1714-1729.
16. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012; 488:96-99.
17. Bredesen DE, John, V.,Galvan, V. Importance of the caspase cleavage site in amyloid-beta protein precursor. J Alzheimers Dis. 2010; 22:57-63.
18. Lourenco FC, Galvan V, Fombonne J, Corset V, Llambi F, Muller U, Bredesen DE and Mehlen P. Netrin-1 interacts with amyloid precursor protein and regulates amyloid-beta production. Cell Death Differ. 2009; 16:655-663.
19. Obregon D, Hou H, Deng J, Giunta B, Tian J, Darlington D, Shahaduzzaman M, Zhu Y, Mori T, Mattson MP and Tan J. Soluble amyloid precursor protein-alpha modulates betasecretase activity and amyloid-beta generation. Nature communications. 2012; 3:777.
20. Lu D, Soriano S, Bredesen D and Koo E. Caspase cleavage of the amyloid precursor protein modulates amyloid beta-protein toxicity. J Neurochem. 2003; 87:733-741.
21. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006; 313:1781-1784.
22. Spilman P, Descamps O, Gorostiza O, Peters-Libeu C, Poksay KS, Matalis A, Campagna J, Patent A, Rao R, John V and Bredesen DE. The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model. Brain Res. 2014; 1551:25-44.
23. Zhang XY, Liu L, Liu S, Hong X, Chen da C, Xiu MH, Yang FD, Zhang Z, Zhang X, Kosten TA and Kosten TR. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. Am J Psychiatry. 2012; 169:974-981.
24. Saganich MJ, Schroeder BE, Galvan V, Bredesen DE, Koo EH and Heinemann SF. Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require Cterminal cleavage of APP. J Neurosci. 2006; 26:13428-13436.
25. Banwait S, Galvan V, Zhang J, Gorostiza OF, Ataie M, Huang W, Crippen D, Koo EH and Bredesen DE. C-terminal cleavage of the amyloid-beta protein precursor at Asp664: a switch associated with Alzheimer's disease. J Alzheimers Dis. 2008;13:1-16.
26. Galvan V, Zhang J, Gorostiza OF, Banwait S, Huang W, Ataie M, Tang H and Bredesen DE. Long-term prevention of Alzheimer's disease-like behavioral deficits in PDAPP mice carrying a mutation in Asp664. Behav Brain Res. 2008; 191:246-255.
27. Heijer T, Skoog I, Oudkerk M, de Leeuw FE, de Groot JC, Hofman A and Breteler MM. Association between blood pressure levels over time and brain atrophy in the elderly. Neurobiol Aging. 2003; 24:307-313.
28. Lan YL, Zhao J and Li S. Update on the Neuroprotective Effect of Estrogen Receptor Alpha Against Alzheimer's Disease. J Alzheimers Dis. 2014.
29. Shi C, Zhu X, Wang J and Long D. Estrogen receptor alpha promotes non-amyloidogenic processing of platelet amyloid precursor protein via the MAPK/ERK pathway. J Steroid Biochem Mol Biol. 2014; 144PB:280-285.
30. Yang Y, Wu Y, Zhang S and Song W. High glucose promotes Abeta production by inhibiting APP degradation. PLoS One. 2013; 8:e69824.
31. Sutinen EM, Pirttila T, Anderson G, Salminen A and Ojala JO. Pro-inflammatory interleukin-18 increases Alzheimer's diseaseassociated amyloid-beta production in human neuron-like cells. Journal of neuroinflammation. 2012; 9:199.
32. Theendakara V, Patent A, Peters Libeu CA, Philpot B, Flores S, Descamps O, Poksay KS, Zhang Q, Cailing G, Hart M, John V, Rao RV and Bredesen DE. Neuroprotective Sirtuin ratio reversed by ApoE4. Proc Natl Acad Sci U S A. 2013; 110:18303-18308.
33. Wade AG, Farmer M, Harari G, Fund N, Laudon M, Nir T, Frydman-Marom A and Zisapel N. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebocontrolled, multicenter trial. Clin Interv Aging. 2014; 9:947-961.
34. Cotman CW, Berchtold NC and Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 2007; 30:464-472.
35. Silberman A, Banthia R, Estay IS, Kemp C, Studley J, Hareras D and Ornish D. The effectiveness and efficacy of an intensive cardiac rehabilitation program in 24 sites. Am J Health Promot. 2010; 24:260-266.
36. Polimeni G, Esposito E, Bevelacqua V, Guarneri C and Cuzzocrea S. Role of melatonin supplementation in neurodegenerative disorders. Front Biosci (Landmark Ed). 2014;19:429-446.
37. Aguiar P, Monteiro L, Feres A, Gomes I and Melo A. Rivastigmine transdermal patch and physical exercises for Alzheimer's disease: a randomized clinical trial. Curr Alzheimer Res. 2014; 11:532-537.
38. Smith JC, Nielson KA, Woodard JL, Seidenberg M, Durgerian S, Hazlett KE, Figueroa CM, Kandah CC, Kay CD, Matthews MA and Rao SM. Physical activity reduces hippocampal atrophy in elders at genetic risk for Alzheimer's disease. Frontiers in aging neuroscience. 2014; 6:61.
39. Smith GE, Housen P, Yaffe K, Ruff R, Kennison RF, Mahncke HW and Zelinski EM. A cognitive training program based on principles of brain plasticity: results from the Improvement in Memory with Plasticity-based Adaptive Cognitive Training (IMPACT) study. J Am Geriatr Soc. 2009; 57:594-603.
40. Hooshmand B, Solomon A, Kareholt I, Leiviska J, Rusanen M, Ahtiluoto S, Winblad B, Laatikainen T, Soininen H and Kivipelto M. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology. 2010;75:1408-1414.
41. Tangney CC, Tang Y, Evans DA and Morris MC. Biochemical indicators of vitamin B12 and folate insufficiency and cognitive decline. Neurology. 2009; 72:361-367.
42. Yaffe K, Haan M, Byers A, Tangen C and Kuller L. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology. 2000; 54:1949-1954.
43. Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF, Teter B, et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther. 2008; 326:196-208.
44. Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, Teng E, Hu S, Chen PP, Maiti P, Teter B, Cole GM and Frautschy SA. Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. J Biol Chem. 2013; 288:4056-4065.
45. Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, Khanna P, Jain SC, Thakur SS and Ravindranath V. Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci U S A. 2012; 109:3510-3515.
46. Zanotta D, Puricelli S and Bonoldi G. Cognitive effects of a dietary supplement made from extract of Bacopa monnieri, astaxanthin, phosphatidylserine, and vitamin E in subjects with mild cognitive impairment: a noncomparative, exploratory clinical study. Neuropsychiatr Dis Treat. 2014; 10:225-230.
47. Li W, Yu J, Liu Y, Huang X, Abumaria N, Zhu Y, Xiong W, Ren C, Liu XG, Chui D and Liu G. Elevation of brain magnesium prevents and reverses cognitive deficits and synaptic loss in Alzheimer's disease mouse model. J Neurosci. 2013; 33:8423-8441.
48. Littlejohns TJ, Henley WE, Lang IA, Annweiler C, Beauchet O, Chaves PH, Fried L, Kestenbaum BR, Kuller LH, Langa KM, Lopez OL, Kos K, Soni M, et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014.
49. Mori K, Obara Y, Hirota M, Azumi Y, Kinugasa S, Inatomi S and Nakahata N. Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. Biol Pharm Bull. 2008; 31:1727-1732.
50. Taglialatela G, Navarra D, Cruciani R, Ramacci MT, Alema GS and Angelucci L. Acetyl-L-carnitine treatment increases nerve growth factor levels and choline acetyltransferase activity in the central nervous system of aged rats. Exp Gerontol. 1994; 29:55-66.
51. Cansev M, Wurtman RJ, Sakamoto T and Ulus IH. Oral administration of circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses. Alzheimers Dement. 2008; 4:S153-168.
52. Parachikova A, Green KN, Hendrix C and LaFerla FM. Formulation of a medical food cocktail for Alzheimer's disease: beneficial effects on cognition and neuropathology in a mouse model of the disease. PLoS One. 2010; 5:e14015.
53. Brewer GJ and Kaur S. Zinc deficiency and zinc therapy efficacy with reduction of serum free copper in Alzheimer's disease. International journal of Alzheimer's disease. 2013;2013:586365.
54. Troussiere AC, Monaca Charley C, Salleron J, Richard F, Delbeuck X, Derambure P, Pasquier F and Bombois S. Treatment of sleep apnoea syndrome decreases cognitive decline in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2014.
55. Bland J. The Disease Delusion: Conquering the Causes of Illness for a Healthier, Longer and Happier Life. 2014; United States: Harper Wave.
56. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ and Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond). 2009;6:31.